

ALAT (GPT) FS* (IFCC mod.)

with/without Pyridoxal-5-Phosphate FS (P-5-P)

Order Information

Cat. No.	Kit size				
1 2701 99 10 021	R1 5 x 20 mL	+	R2	1 x 25 mL	
1 2701 99 10 026	R1 5 x 80 mL	+	R2	1 x 100 mL	
1 2701 99 10 023	R1 1 x 800 mL	+	R2	1 x 200 mL	
1 2701 99 10 704	R1 8 x 50 mL	+	R2	8 x 12.5 mL	
1 2701 99 10 917	R1 8 x 60 mL	+	R2	8 x 15 mL	
1 2701 99 90 314	R1 10 x 20 mL	+	R2	2 x 30 mL	

For determination with P-5-P additionally required:
2 5010 99 10 030 6 x 3 mL

Intended Use


Diagnostic reagent for quantitative in vitro determination of ALAT (GPT) in human serum or heparin plasma on automated photometric systems.

Summary

Alanine Aminotransferase (ALAT/ALT), formerly called Glutamic Pyruvic Transaminase (GPT) and Aspartate Aminotransferase (ASAT/AST), formerly called Glutamic Oxalacetic Transaminase (GOT) are the most important representatives of a group of enzymes, the aminotransferases or transaminases, which catalyze the conversion of α -keto acids into amino acids by transfer of amino groups. As a liver specific enzyme, ALAT is only significantly elevated in hepatobiliary diseases. Increased ASAT levels, however, can occur in connection with damages of heart or skeletal muscle as well as of liver parenchyma. Parallel measurement of ALAT and ASAT is, therefore, applied to distinguish liver from heart or skeletal muscle damages. The ASAT/ALAT ratio is used for differential diagnosis in liver diseases. While ratios < 1 indicate mild liver damage, ratios > 1 are associated with severe, often chronic liver diseases. [1,2]

Method

Optimized UV-test according to IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) [modified]



Addition of pyridoxal-5-phosphate (P-5-P), recommended by IFCC, stabilizes the activity of transaminases and avoids falsely low values in samples containing insufficient endogenous P-5-P, e.g. from patients with myocardial infarction, liver disease and intensive care patients [1,3].

Reagents**Components and Concentrations**

R1:	TRIS	pH 7.15	140 mmol/L
	L-Alanine		700 mmol/L
	LDH (lactate dehydrogenase)		≥ 2300 U/L
R2:	2-Oxoglutarate		85 mmol/L
	NADH		1 mmol/L
Pyridoxal-5-Phosphate FS			
	Good's buffer	pH 9.6	100 mmol/L
	Pyridoxal-5-phosphate		13 mmol/L

Storage and Stability

Reagents are stable up to the date of expiry indicated on the kit, if stored at 2 – 8°C and contamination is avoided. Do not freeze and protect from light.

Warnings and Precautions

- The reagents contain sodium azide (0.95 g/L) as preservative. Do not swallow! Avoid contact with skin and mucous membranes.
- Reagent 1 contains animal and biological material. Handle the product as potentially infectious according to universal precautions and good clinical laboratory practice.
- Reagent 2 contains biological material. Handle the product as potentially infectious according to universal precautions and good clinical laboratory practice.
- Sulfasalazine and sulfapyridine medication may cause false results in patient samples. Blood collection must be performed prior to drug administration.
- In very rare cases, samples of patients with gammopathy might give falsified results [4].
- Please refer to the safety data sheets and take the necessary precautions for the use of laboratory reagents. For diagnostic purposes, the results should always be assessed with the patient's medical history, clinical examinations and other findings.
- For professional use only.

Waste Management

Refer to local legal requirements.

Reagent Preparation

The reagents are ready to use.

For determination with P-5-P mix 1 part of P-5-P with 100 parts of reagent 1,

e.g. 100 μ L P-5-P + 10 mL R1

Stability after mixing:	6 days	at	2 – 8°C
	24 hours	at	15 – 25°C

Materials Required

General laboratory equipment

Specimen

Human serum or heparin plasma

Stability [5]:

3 days	at	20 – 25°C
7 days	at	4 – 8°C
7 days	at	-20°C

Only freeze once. Discard contaminated specimens.

Assay Procedure

Basic settings for BioMajesty® JCA-BM6010/C

Wavelength	340/410 nm
Temperature	37°C
Measurement	Kinetic
Sample/Calibrator	6.0 μ L
Reagent 1	80 μ L
Reagent 2	20 μ L
Addition reagent 2	Cycle 19 (286 s)
Absorbance 1	-
Absorbance 2	Cycle 25/42 (367 s/600 s)
Calibration	Linear

Calculation

With calibrator

$$\text{ALAT [U/L]} = \frac{\Delta A/\text{min. Sample}}{\Delta A/\text{min. Cal}} \times \text{Conc. Cal [U/L]}$$

Conversion Factor

$$\text{ALAT [U/L]} \times 0.0167 = \text{ALAT [\mu kat/L]}$$

Calibrators and Controls

DiaSys TruCal U calibrator is recommended for calibration. This method has been standardized against the original IFCC formulation. Use DiaSys TruLab N and P for internal quality control. Each laboratory should establish corrective action in case of deviating measurement in control recovery.

	Cat. No.	Kit size
TruCal U	5 9100 99 10 063	20 x 3 mL
	5 9100 99 10 064	6 x 3 mL
TruLab N	5 9000 99 10 062	20 x 5 mL
	5 9000 99 10 061	6 x 5 mL
TruLab P	5 9050 99 10 062	20 x 5 mL
	5 9050 99 10 061	6 x 5 mL

Performance Characteristics

Data evaluated on BioMajesty® JCA-BM6010/C

Exemplary data mentioned below may slightly differ in case of deviating measurement conditions.

with P-5-P

Measuring range up to 1000 U/L. When values exceed this range, samples should be diluted 1 + 9 with NaCl solution (9 g/L) and the result multiplied by 10.	
Limit of detection**	4 U/L

Interfering substance	Interferences ≤ 10% up to	Analyte concentration [U/L]
Ascorbic acid	30 mg/dL	36.0
	60 mg/dL	110
Bilirubin (conjugated)	54 mg/dL	36.0
	60 mg/dL	120
Bilirubin (unconjugated)	54 mg/dL	36.0
	60 mg/dL	106
Hemoglobin	500 mg/dL	36.0
	500 mg/dL	118
Lipemia (triglycerides)	400 mg/dL	36.0
	900 mg/dL	99.2

For further information on interfering substances refer to Young DS [6.7].

Precision			
Within run (n=20)	Sample 1	Sample 2	Sample 3
Mean [U/L]	26.0	33.7	191
CV [%]	2.67	1.37	0.801
Total Precision CLSI (n=80)	Sample 1	Sample 2	Sample 3
Mean [U/L]	23.5	42.6	505
CV [%]	3.82	1.76	0.975

Method comparison (n=154)	
Test x	Competitor ALAT (GPT) (cobas® c 501)
Test y	DiaSys ALAT (GPT) FS (BioMajesty® JCA-BM6010C)
Slope	1.08
Intercept	0.771 U/L
Coefficient of correlation	0.990

without P-5-P

Measuring range up to 1000 U/L.
When values exceed this range, samples should be diluted 1 + 9 with NaCl solution (9 g/L) and the result multiplied by 10.

Limit of detection**	6 U/L
----------------------	-------

Interfering substance	Interferences ≤ 10% up to	Analyte concentration [U/L]
Ascorbic acid	30 mg/dL	40.0
	60 mg/dL	84.8
Bilirubin (conjugated)	60 mg/dL	40.0
	60 mg/dL	97.1
Bilirubin (unconjugated)	55 mg/dL	40.0
	60 mg/dL	81.3
Hemoglobin	500 mg/dL	40.0
	1000 mg/dL	98.6
Lipemia (triglycerides)	400 mg/dL	40.0
	1000 mg/dL	76.3

For further information on interfering substances refer to Young DS [6.7].

Precision			
Within run (n=20)	Sample 1	Sample 2	Sample 3
Mean [U/L]	21.4	34.5	191
CV [%]	2.45	1.54	0.853
Total Precision CLSI (n=80)	Sample 1	Sample 2	Sample 3
Mean [U/L]	19.9	36.1	393
CV [%]	2.76	1.98	0.917

Method comparison (n=154)	
Test x	Competitor ALAT (GPT) (cobas® c 501)
Test y	DiaSys ALAT (GPT) FS (BioMajesty® JCA-BM6010C)
Slope	1.07
Intercept	1.33 U/L
Coefficient of correlation	0.994

** according to CLSI document EP17-A2, Vol. 32, No. 8

Reference Range

With P-5-P			
Women [8]		< 34 U/L	< 0.57 μkat/L
Men [8]		< 45 U/L	< 0.75 μkat/L
Children [1]	1 – 30 Day(s)	< 25 U/L	< 0.42 μkat/L
	2 – 12 Months	< 35 U/L	< 0.58 μkat/L
	1 – 3 Year(s)	< 30 U/L	< 0.50 μkat/L
	4 – 6 Years	< 25 U/L	< 0.42 μkat/L
	7 – 9 Years	< 25 U/L	< 0.42 μkat/L
	10 – 18 Years	< 30 U/L	< 0.50 μkat/L

Without P-5-P		
Women [9,10]	< 31 U/L	< 0.52 μkat/L
Men [9,10]	< 41 U/L	< 0.68 μkat/L

Each laboratory should check if the reference ranges are transferable to its own patient population and determine own reference ranges if necessary.

Literature

1. Thomas L. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST). In: Thomas L, editor. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 55-65.
2. Moss DW, Henderson AR. Clinical enzymology. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B Saunders Company; 1999. p. 617-721.
3. Bergmeyer HU, Horder M, Rej R. Approved Recommendation (1985) on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes. L.Clin. Chem. Clin. Biochem 1986; 24: 481-495.
4. Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. ClinChemLabMed 2007;45(9):1240-1243.
5. Guder WG, Zawta B et al. The Quality of Diagnostic Samples. 1st ed. Darmstadt: GIT Verlag; 2001; 14-5.
6. Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th ed. Volume 1 and 2. Washington, DC: The American Association for Clinical Chemistry Press 2000.
7. Young DS. Effects on Clinical Laboratory Tests - Drugs Disease, Herbs & Natural Products, <https://clinf.wiley.com/aaccweb/aacc/>, accessed in September 2021. Published by AACC Press and John Wiley and Sons, Inc.
8. Schumann G, Bonora R, Ceriotti F, Féraud G et al. IFCC primary reference procedure for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 4: Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med 2002;40:718-24.
9. Lorentz K, Röhle G, Siekmann L. Einführung der neuen Standardmethoden 1994 zur Bestimmung der katalytischen Enzymkonzentrationen bei 37 °C. DG Klinische Chemie Mitteilungen 1995; Heft 4.
10. Zawta B, Klein G, Bablok W. Temperature Conversion in Clinical Enzymology? Klin. Lab. 1994; 40: 33-42.



DiaSys Diagnostic Systems GmbH
Alte Strasse 9 65558 Holzheim
Germany
www.diasys-diagnostics.com

* Fluid Stable